10x Genomics, Inc. (TXG) Stock Analysis: Navigating Opportunities Amidst a Complex Valuation Landscape
Genomics, Inc. (NASDAQ: TXG), a trailblazer in the medical devices sector, stands at a pivotal juncture as it continues to ...
Model output · Signal date 2026-10-14
10x Genomics, Inc. (TXG) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 4004 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$9.35B
mid-cap · #8 of 25 peers
Summary
10x Genomics, Inc. (TXG) stock forecast summary
Our AI ranks 10x Genomics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
10x Genomics, Inc. is a mid-cap company with a market capitalization of $9.35B. It ranks number 8 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast. Its Gross Margin of 70.0% is the highest of the 19 peers that report one.
A per-ticker accuracy statistic for TXG is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TXG included.
Follow TXG freePrice
TXG price chart and AI forecast
Cross-section · 2026-10-14
How TXG ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
10x Genomics, Inc. (TXG) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | TXG | Rank |
|---|---|---|
| Market Cap | $9.35B | 8/25 |
| P/B Ratio | 11.33x | 3/23 |
| EPS | $-0.49 | – |
| Book Value/Share | $6.34 | – |
| Revenue/Share | $4.73 | – |
| FCF/Share | $0.93 | – |
Profitability & Margins
| Metric | TXG | Rank |
|---|---|---|
| ROE | -9.1% | 9/21 |
| ROA | -7.3% | 10/22 |
| ROIC | -9.7% | 10/21 |
| Gross Margin | 70.0% | 1/19 |
| Operating Margin | -14.3% | 11/21 |
| Net Margin | -12.2% | 9/20 |
| EBT Margin | -12.1% | 12/22 |
| Tax Rate | -0.3% | – |
Financial Health
| Metric | TXG | Rank |
|---|---|---|
| Current Ratio | 5.69x | 6/25 |
| Quick Ratio | 5.25x | 5/24 |
| D/E Ratio | 0.25x | 19/24 |
| Financial Leverage | 1.25x | 19/24 |
| Interest Coverage | -6898.5x | 21/21 |
| Working Capital | $556M | 8/25 |
Cash Flow
| Metric | TXG | Rank |
|---|---|---|
| Operating Cash Flow | $127M | 9/24 |
| Free Cash Flow | $121M | 7/20 |
| Capital Spending | -$6M | 12/20 |
| OCF Growth YoY | 89.8% | 1/12 |
| FCF Growth YoY | 113.5% | 1/11 |
| FCF/Sales | 19.7% | 3/19 |
| CapEx/Sales | 0.9% | 18/19 |
Operational Efficiency
| Metric | TXG | Rank |
|---|---|---|
| Asset Turnover | 0.60x | 7/21 |
| Receivables Turnover | 13.0x | 1/19 |
| Inventory Turnover | 3.5x | 4/19 |
| Fixed Assets Turnover | 2.9x | 18/21 |
| Days Sales Outstanding | 28 days | 19/19 |
| Days Inventory | 104 days | 16/19 |
| Payables Period | 41 days | 12/18 |
| Cash Conversion Cycle | 91 days | 15/17 |
Income Statement
| Metric | TXG | Rank |
|---|---|---|
| Total Revenue | $616M | 9/21 |
| Operating Income | -$88M | 17/21 |
| Net Income | -$75M | 16/22 |
| R&D Expense | $227M | 7/21 |
| SG&A Expense | $297M | 9/20 |
| Cost of Goods Sold | $185M | 8/19 |
Dividend & Shareholder Information
| Metric | TXG | Rank |
|---|---|---|
| Shares Outstanding | 130M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $675M | 65.5% of assets |
| Cash & Short-term Investments | $503M | 48.8% of assets |
| Accounts Receivable | $48M | 4.6% of assets |
| Inventory | $53M | 5.1% of assets |
| Total Liabilities | $205M | 19.9% of assets |
| Short-term Debt | $98M | 9.5% of assets |
Quarterly Financial Reports
TXG quarterly financials and insider trading
Industry Peers · Laboratory Analytical Instruments
10x Genomics, Inc. (TXG) industry peers
Companies classified under the same SEC industry code as 10x Genomics, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| TXG 10x Genomics, Inc. | ▲ | $9.35B |
| A Agilent Technologies, Inc. | ▼ | $48.38B |
| WAT Waters Corp /De/ | ▲ | $42.17B |
| ILMN Illumina, Inc. | ▶ | $40.95B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.02B |
| RVTY Revvity, Inc. | ▼ | $17.30B |
| AVTR Avantor, Inc. | ▶ | $10.62B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.73B |
| BRKR Bruker Corp | ▲ | $8.56B |
| ALMR Alamar Biosciences, Inc. | ▶ | $1.63B |
| CTKB Cytek Biosciences, Inc. | ▲ | $695M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $637M |
| MASS 908 Devices Inc. | ▲ | $500M |
| EYPT Eyepoint, Inc. | ▲ | $265M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $261M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $250M |
| QTRX Quanterix Corp | ▲ | $149M |
| SEER Seer, Inc. | ▶ | $117M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $44M |
| PRPO Precipio, Inc. | ▲ | $40M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $11M |
| SCND Scientific Industries Inc | ▲ | $8M |
Where TXG sits on the market map
Industrial Applications and Services · Laboratory Analytical Instruments
News
10x Genomics, Inc. (TXG) stock news
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and ...
TXG - 10x Genomics, Inc.
10x Genomics, Inc. is currently listed on NASDAQ under TXG. One share of TXG stock can currently be purchased for approximately $72.72. Is 10x Genomics, Inc. listed on the NASDAQ or NYSE? 10x Genomics ...
FAQ
10x Genomics, Inc. (TXG) stock forecast FAQ
What is the 10x Genomics, Inc. (TXG) stock forecast?
Our AI ranks 10x Genomics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are 10x Genomics, Inc. stock predictions?
A per-ticker accuracy statistic for TXG is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are 10x Genomics, Inc. forecasts updated?
10x Genomics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are 10x Genomics, Inc.'s industry peers?
25 issuers in our coverage, TXG included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.